What it is and what it is used for

for

Boostrix-IPV is a vaccine used as a booster dose in children from 3 years onwards, teenagers and adults to prevent four diseases: diphtheria, tetanus (lockjaw), pertussis (whooping cough) and poliomyelitis (polio). The vaccine works by causing the body to produce its own protection (antibodies) against these diseases. •

Diphtheria: Diphtheria mainly affects the airways and sometimes the skin. Generally the airways become inflamed (swollen) causing severe breathing difficulties and sometimes suffocation. The bacteria also release a toxin (poison), which can cause nerve damage, heart problems, and even death.

•

Tetanus (Lockjaw): Tetanus bacteria enter the body through cuts, scratches or wounds in the skin. Wounds that are especially prone to infection are burns, fractures, deep wounds or wounds contaminated with soil, dust, horse manure/dung or wood splinters. The bacteria release a toxin (poison), which can cause muscle stiffness, painful muscle spasms, fits and even death. The muscle spasms can be strong enough to cause bone fractures of the spine.

•

Pertussis (Whooping cough): Pertussis is a highly infectious illness. The disease affects the airways causing severe spells of coughing that may interfere with normal breathing. The coughing is often accompanied by a "whooping" sound, hence the common name "whooping cough". The cough may last for 1-2 months or longer. Pertussis can also cause ear infections, bronchitis which may last a long time, pneumonia, fits, brain damage and even death.

•

Poliomyelitis (Polio): Poliomyelitis, sometimes called simply "polio" is a viral infection that can have variable effects. Often it causes only a mild illness but in some people it causes permanent damage or even death. In its severest form, polio infection causes paralysis of the muscles (muscles cannot move), including those muscles needed for breathing and walking. The limbs affected by the disease may be painfully deformed.

None of the ingredients in the vaccine can cause diphtheria, tetanus, whooping cough or poliomyelitis. The use of Boostrix-IPV during pregnancy will help to protect your baby from whooping cough in the first few months of life before he/she receives the primary immunisation. 1

2.

What you need to know before you or your child receive Boostrix IPV

Boostrix-IPV should not be given: •

if you or your child have previously had any allergic reaction to Boostrix-IPV, or any of the other ingredients of this vaccine (listed in section 6) or neomycin, polymyxin (antibiotics) or formaldehyde. Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.

•

if you or your child have previously had an allergic reaction to any vaccine against diphtheria, tetanus, pertussis (whooping cough) or poliomyelitis diseases.

•

if you or your child experienced problems of the nervous system (encephalopathy) within 7 days after previous vaccination with a vaccine against pertussis (whooping cough) disease.

•

if you or your child experienced a temporary reduction in blood platelets (which increases risk of bleeding or bruising) or problems with the brain or nerves after previous vaccination with a vaccine against diphtheria and/or tetanus.

•

if you or your child have a severe infection with a high temperature (over 38°C). A minor infection should not be a problem, but talk to your doctor first.

Warnings and precautions Talk to your doctor or pharmacist before you or your child are given Boostrix IPV: •

if after previously having Boostrix-IPV or another vaccine against pertussis (whooping cough) disease, you or your child had any problems, especially: –

A high temperature (over 40°C) within 48 hours of vaccination A collapse or shock-like state within 48 hours of vaccination Persistent crying lasting 3 hours or more within 48 hours of vaccination Seizures/fits with or without a high temperature within 3 days of vaccination

•

if your child is suffering from an undiagnosed or progressive disease of the brain or uncontrolled epilepsy. After control of the disease the vaccine should be administered.

•

if you or your child have a bleeding problem or bruise easily

•

if you or your child have a tendency to seizures/fits due to a fever, or if there is a family history of this

•

if you or your child have long standing immune system problems due to any reason (including HIV infection). You or your child may still be given Boostrix-IPV but the protection against infections after having the vaccine may not be as good as in children or adults with good immunity to infections.

Fainting can occur (mostly in adolescents) following, or even before, any needle injection. Therefore tell the doctor or nurse if you or your child fainted with a previous injection. As with all vaccines, Boostrix-IPV may not completely protect all people who are vaccinated. Other medicines and Boostrix-IPV Tell your doctor or pharmacist if you or your child is/are taking, have recently taken or might take any other medicines, or have/has recently received any other vaccine. Boostrix-IPV can be given at the same time as some other vaccines. A different injection site will be used for each type of vaccine. Boostrix-IPV may not work as well if you or your child are taking medicines that reduce the effectiveness of your/their immune system to fight infection. 2

Pregnancy and breastfeeding If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this vaccine. It is not known if Boostrix-IPV passes into breast milk. Your doctor will discuss with you the possible risks and benefits of having Boostrix -IPV during breastfeeding. Driving and using machines Boostrix-IPV is unlikely to produce an effect on the ability to drive and use machines. Boostrix-IPV contains neomycin and polymyxin This vaccine contains neomycin and polymyxin (antibiotics). Please tell your doctor if you or your child have had an allergic reaction to these ingredients. Boostrix-IPV contains para-aminobenzoic acid, phenylalanine, sodium and potassium Boostrix-IPV contains para-aminobenzoic acid. It may cause allergic reactions (possibly delayed), and exceptionally, bronchospasm. This medicine contains 0.0298 microgram phenylalanine in each dose. Phenylalanine may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly. This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodiumfree'. This medicine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially 'potassiumfree'.

3.

How to take it

•

Boostrix-IPV will be given as an injection into the muscle.

•

The vaccine should never be given into blood vessels.

•

You or your child will receive a single injection of Boostrix-IPV.

•

Your doctor will verify if you or your child have previously received vaccines against diphtheria, tetanus, pertussis and/or polio.

•

Boostrix-IPV may be used in case of a suspected infection with tetanus, although additional provisions, i.e. elaborate wound dressing and/or application of Tetanus-Anti-Toxin will be taken as well to reduce the risk of manifestation of the disease.

•

Your doctor will give you advice on repeat vaccination.

4.

Possible side effects

Like all medicines, this vaccine can cause side effects, although not everybody gets them. As with all injectable vaccines severe allergic reactions (anaphylactic and anaphylactoid reactions) may occur very rarely (with up to 1 in 10,000 doses of the vaccine). These can be recognised by: • • • •

Rashes that may be itchy or blistering, Swelling of the eyes and face, Difficulty in breathing or swallowing, A sudden drop in blood pressure and loss of consciousness.

3

Such reactions may occur before leaving the doctor's surgery. However, if you or your child get any of these symptoms you should contact a doctor immediately.

Side effects that occurred during clinical trials in children from the age of 4 to 8 years Very common (these may occur with more than 1 in 10 doses of the vaccine): pain, redness and swelling at the injection site, sleepiness. Common (these may occur with up to 1 in 10 doses of the vaccine): fever equal to or greater than 37.5°C (including fever greater than 39°C), bleeding, itching and hard lump at the injection site, large swelling of the vaccinated limb, loss of appetite, irritability, headache. Uncommon (these may occur with up to 1 in 100 doses of the vaccine): diarrhoea, nausea, vomiting, stomach pain, swollen glands in the neck, armpit or groin (lymphadenopathy), sleeping problems, apathy, dry throat, tiredness. Co-administration with measles-mumps-rubella (MMR) or measles-mumps-rubella-varicella (MMRV) vaccines in children aged 3-6 years In studies where Boostrix-IPV was given at the same time as a MMR or MMRV vaccine; skin rash and upper respiratory tract infection (including runny nose and sore throat) were commonly reported. Fever, irritability, fatigue, loss of appetite and gastrointestinal disorders (including diarrhoea and vomiting) were reported more frequently (very common) than in studies where Boostrix-IPV was given alone. Side effects that occurred during clinical trials in adults, teenagers and children from the age of 10 years onwards: Very common (these may occur with more than 1 in 10 doses of the vaccine): pain, redness and swelling at the injection site, tiredness, headache. Common (these may occur with up to 1 in 10 doses of the vaccine): fever equal to or greater than 37.5°C, bruising, itching, hard lump, warmth and/or numbness at the injection site, stomach pain, nausea, vomiting. Uncommon (these may occur with up to 1 in 100 doses of the vaccine): fever greater than 39°C, large swelling of the vaccinated limb, chills, pain, dizziness, joint pain, muscle ache, itching, oral herpes, swollen glands in the neck, armpit or groin (lymphadenopathy), decreased appetite, tingling or numbness of the hands or feet (paraesthesia), sleepiness, asthma. The following side effects occurred during routine use of Boostrix-IPV and are not specific for any age group: collapse or periods of unconsciousness or lack of awareness, swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema), seizures or fits (with or without fever), hives (urticaria), unusual weakness (asthenia). Additionally, the following side effects have been reported during clinical trials with Boostrix (GlaxoSmithKline Biologicals' booster vaccine against diphtheria, tetanus and pertussis): Side effects that occurred in children from the age of 4 to 8 years Uncommon (these may occur with up to 1 in 100 doses of the vaccine): disturbances in attention, discharge with itching of the eyes and crusty eyelids (conjunctivitis), pain.

Possible side effects

that occurred in adults, teenagers and children from the age of 10 years onwards

4

Very common (these may occur with more than 1 in 10 doses of the vaccine): generally feeling unwell. Common (these may occur with up to 1 in 10 doses of the vaccine): hard lump or abscess at the injection site. Uncommon (these may occur with up to 1 in 100 doses of the vaccine): upper respiratory tract infection, sore throat and discomfort when swallowing (pharyngitis), fainting (syncope), cough, diarrhoea, excessive sweating (hyperhidrosis), skin rash, joint stiffness, joint and muscle stiffness, flulike symptoms, such as fever, sore throat, runny nose, cough and chills. Following administration of vaccines against tetanus a temporary inflammation of the nerves, causing pain, weakness and paralysis in the extremities and often progressing to the chest and face have been reported very rarely (with up to 1 in 10,000 doses of the vaccine) (Guillain-Barré syndrome). Reporting of side effects If you or your child get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.

How to store it

Boostrix-IPV

Keep this vaccine out of the sight and reach of children. Do not use this vaccine after the expiry date which is stated on the carton and the pre-filled syringe label after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2C – 8C). Do not freeze. Freezing destroys the vaccine. Store in the original package in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you or your child no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Boostrix-IPV contains –

The active substances are: Diphtheria toxoid1 Tetanus toxoid1 Bordetella pertussis antigens Pertussis toxoid1 Filamentous Haemagglutinin1 Pertactin1 Inactivated poliovirus type 1 (Mahoney strain)2 type 2 (MEF-1 strain)2 type 3 (Saukett strain)2

not less than 2 International Units (IU) (2.5 Lf) not less than 20 International Units (IU) (5 Lf) 8 micrograms 8 micrograms 2.5 micrograms 40 D-antigen unit 8 D-antigen unit 32 D-antigen unit

1

adsorbed on aluminium hydroxide, hydrated (Al(OH)3) and aluminium phosphate (AlPO4) 5

0.3 milligrams Al3+ 0.2 milligrams Al3+

2propagated in VERO cells Aluminium hydroxide and aluminium phosphate are included in this vaccine as adjuvants. Adjuvants are substances included in certain vaccines to accelerate, improve and/or prolong the protective effects of the vaccine. –

The other ingredients are: Medium 199 (containing amino acids (including phenylalanine), mineral salts (including sodium and potassium), vitamins (including para-aminobenzoic acid) and other substances), sodium chloride and water for injections.

What Boostrix-IPV looks like and contents of the pack Suspension for injection in pre-filled syringe. Boostrix -IPV is a white, slightly milky liquid presented in a pre-filled syringe (0.5 ml). Boostrix-IPV is available in 1-dose pre-filled syringe with or without separate needles, pack sizes of 1 and 10. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: SmithKline Beecham Ltd, 79 New Oxford Street, London, WC1A 1DG, United Kingdom

Manufacturer: GlaxoSmithKline Biologicals S.A. Rue de l'Institut 89 B-1330 Rixensart Belgium Other formats: To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK only) Please be ready to give the following information: Product name

Boostrix-IPV

Reference number

10592/0214

This is a service provided by the Royal National Institute of Blind People. This leaflet was last revised in November 2024 Trade marks are owned by or licensed to the GSK group of companies. © 2024 GSK group of companies or its licensor. Other sources of information Detailed information on this medicine is available on the web site of: the Medicines and Healthcare Products Regulatory Agency (MHRA) 6

————————————————————————————————————————–The following information is intended for healthcare professionals only: Prior to use, the vaccine should be at room temperature and well shaken in order to obtain a homogeneous turbid white suspension. Prior to administration, the vaccine should be visually inspected for any foreign particulate matter and/or variation of physical aspect. In the event of either being observed, do not administer the vaccine. Instructions for the pre-filled syringe

Luer Lock Adaptor

Hold the syringe by the barrel, not by the plunger. Unscrew the syringe cap by twisting it

Plunger

anticlockwise.

Barrel Cap

Needle hub

To attach the needle, connect the hub to the Luer Lock Adaptor and rotate a quarter turn clockwise until you feel it lock. Do not pull the syringe plunger out of the barrel. If it happens, do not administer the vaccine.

Disposal: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7